Scott Lewis, DO
Rheumatology · Somerset, KYNPI 1336368505
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.2% of the total across 1,292 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 32 manufacturers, the largest accounting for just 17.2% — the pattern of someone who eats at a lot of different presentations.
Across 1,292 payments — averaging $15.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$3K
- Amgen$3K
- Novartis$2K
- Johnson & Johnson$2K
- Pfizer$2K
- AstraZeneca$1K
- plus $6K from 26 others
Across 4 payments — averaging $12,660 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$29K
- Novartis$22K
What the payments were for
- Food & beverage$19,26898%
- Education$3452%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 209 | $3,376 |
| Amgen(2 entities) | 237 | $3,044 |
| Novartis | 118 | $2,140 |
| Johnson & Johnson(2 entities) | 106 | $1,903 |
| Pfizer | 140 | $1,577 |
| AstraZeneca(2 entities) | 65 | $1,361 |
| UCB, Inc. | 89 | $1,277 |
| E.r. Squibb & Sons, L.L.C. | 83 | $1,204 |
| GSK | 56 | $921 |
| Lilly USA, LLC | 46 | $480 |
| Mallinckrodt Hospital Products Inc. | 12 | $283 |
| Aurinia Pharma U.S., Inc. | 20 | $234 |
| Boehringer Ingelheim | 11 | $216 |
| Pacira Therapeutics, Inc. | 15 | $197 |
| Radius Health, Inc. | 11 | $184 |
| Sobi, Inc | 9 | $152 |
| Bristol Myers Squibb | 18 | $140 |
| Sanofi | 4 | $133 |
| ANI Pharmaceuticals, Inc. | 6 | $119 |
| Regeneron Healthcare Solutions, Inc. | 7 | $119 |
| Organon | 6 | $94 |
| Fresenius Kabi USA, LLC | 5 | $79 |
| Sandoz | 4 | $71 |
| Mallinckrodt Enterprises LLC | 3 | $66 |
| Genentech USA, Inc. | 4 | $60 |
| Tersera Therapeutics LLC | 2 | $53 |
| Globus Medical | 1 | $44 |
| Kyowa Kirin, Inc. | 1 | $23 |
| Almatica Pharma LLC | 1 | $19 |
| Actelion Pharmaceuticals US, Inc. | 1 | $18 |
| Orthogenrx Inc. | 1 | $14 |
| Ascend Therapeutics US, LLC | 1 | $12 |
How this compares
$19,613 in reported general payments places this provider in the 80th percentile of 81 rheumatology providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Humira(Cf) PenAdalimumab | 148 | $1,227,424 |
| ActharCorticotropin | 23 | $996,045 |
| Orencia ClickjectAbatacept | 133 | $768,466 |
| Enbrel SureclickEtanercept | 84 | $623,366 |
| RinvoqUpadacitinib | 56 | $368,968 |
| Xeljanz XrTofacitinib Citrate | 54 | $312,750 |
| BenlystaBelimumab | 62 | $299,014 |
| Actemra ActpenTocilizumab | 59 | $225,082 |
| Cimzia (2 Pack)Certolizumab Pegol | 37 | $218,955 |
| OtezlaApremilast | 44 | $210,088 |
| SimponiGolimumab | 22 | $182,351 |
| Cosentyx Sensoready (2 Pens)Secukinumab | 21 | $156,107 |
| KineretAnakinra | 16 | $90,577 |
| KevzaraSarilumab | 18 | $78,264 |
| Humira(Cf)Adalimumab | 11 | $74,344 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Mallinckrodt Hospital Products Inc.Acthar | $283 | $996,04523 claims |
| AbbVieRinvoq, Humira(Cf) | $3,376 | $443,31267 claims |
| AmgenOtezla, Prolia, Evenity (2 Syringes) | $3,044 | $319,52998 claims |
| GSKBenlysta | $921 | $299,01462 claims |
| UCB, Inc.Cimzia (2 Pack) | $1,277 | $218,95537 claims |
| Johnson & JohnsonSimponi | $1,903 | $182,35122 claims |
| SanofiKevzara | $133 | $78,26418 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 81 rheumatology providers in Kentucky.
Other rheumatology in Somerset
- Timothy LoneskySomerset$32K
- Asad FraserBowling Green$355K
- Rebecca CallisFlorence$272K
- Gary CrumpLouisville$176K
- Benjamin BooneLouisville$80K
- Jacquelyn SmithLouisville$63K
- Neha PansuriaBowling Green$39K
- Mansoor AhmedRichmond$29K
- Liza VargheseCrestview Hills$29K
- Lisa JuneLouisville$27K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.